Sanofi’s Zaltrap Rejected by England’s Health-Cost Agency

Sanofi’s cancer drug Zaltrap was rejected by England’s cost regulator, which said the drug isn’t cost effective even after the company offered a discount.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.